전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved318 programs
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CAR30-NK (EB-CAR30-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CAR5-NK (EB-CAR5-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CARMSLN-NK (EB-CARMSLN-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DUO-CAR-NK-CEA/GCC (EB-DUO-CAR-NK-CEA/GCC)

Colorectal Cancer; Metastatic Colorectal Adenocarcinoma · CEA

#CEA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-G3B7-NK dual-target CAR-NK cells (EB-G3B7-NK dual-target CAR-NK cells)

Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer · Advanced Hepatocellular Carcinoma (HCC)

#AdvancedHepatocellularCarcinomaH#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

EPCAM CAR-T (EPCAM CAR-T)

Advanced Hepatocellular Carcinoma; Advanced Colorectal Cancer · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleEutilexPhase 1

EU307 CAR-T Cell (EU307 CAR-T Cell)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleTianjin Medical University Canc…Preclinical

Enituzumab injection+Abesili tablets+Anastrozole tablets (Enituzumab injection+Abesili tablets+Anastrozole tablets)

Advanced HR+ HER2 Negative Breast Carcinoma · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#AdvancedHR+HER2NegativeBreastCar+1
Trials 1Status Active
AntibodyLimited DatastaleFox Chase Cancer CenterPhase 2

pembrolizumab (Keytruda, Epacadostat + pembrolizumab)

Recurrent/ Metastatic Endometrial Carcinoma · Recurrent/ Metastatic Endometrial Carcin

#RecurrentMetastaticEndometrialCa#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Discontinued
AntibodyLimited DatastaleBoehringer IngelheimPhase 1

Ezabenlimab (Ezabenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Boehringer
Trials 1Status Recruiting
CGTLimited DatastaleUTC Therapeutics Inc.Phase 1

FAST LACO-Stim CDH17 CAR-T (FAST LACO-Stim CDH17 CAR-T)

Biliary Tract Cancer; Colorectal Carcinoma · Biliary Tract Cancer

#BiliaryTractCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleMedical University of ViennaPhase 2

atezolizumab (Tecentriq, FMT combined with Atezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Medical
Trials 1Status Active
CGTLimited DatastaleBaylor College of MedicinePhase 1

GLYCAR T cells (GLYCAR T cells)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleEssen BiotechPhase 2

GPC3 CD146 CAR-T cells (GPC3 CD146 CAR-T cells)

Ovarian Cancer; Ovarian Carcinoma · Ovarian Cancer

#OvarianCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital of G…Phase 1

GPC3 and/or TGFβ targeting CAR-T cells (GPC3 and/or TGFβ targeting CAR-T cells)

Hepatocellular Carcinoma; Immunotherapy · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

GPC3-CART cells (GPC3-CART cells)

Hepatocellular Carcinoma (HCC) · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleSuzhou Kintor Pharmaceutical In…Phase 2

nivolumab (Opdivo, GT90001 and Nivolumab)

Metastatic Hepatocellular Carcinoma; HCC · Metastatic Hepatocellular Carcinoma

#MetastaticHepatocellularCarcinom#Antibody#Phase2#monoclonal-antibody#HCC+1
Trials 1Status Active

10 / 16 pages

← PreviousNext →